JUNSHI BIO (01877) signs licensing agreement involving two dual-target fusion proteins for the treatment of malignant tumors.

JUNSHI BIO (01877) announced that the company has recently signed a "License Agreement" with the licensor. According to the License Agreement, the licensor grants the company exclusive license rights and sub-license rights in the Greater China region (including Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, and Taiwan) to develop, manufacture, use, import, export, sell, and commercialize two dual-target fusion proteins. At the same time, the company and the licensor will have ownership rights in a 50%:50% equity ratio to develop, manufacture, use, import, export, sell, and commercialize one of the licensed products globally. The company will make corresponding upfront payments, milestone payments, and sales royalties to the licensor based on the project progress, while the licensor may pay sub-license income outside the Greater China region to the company. The subject of this transaction is two dual-target fusion proteins (i.e., License Product 1 and License Product 2), mainly used for the treatment of malignant tumors. Currently, License Product 1 is in overseas Phase I clinical trial stage, and the company has submitted an application to the National Medical Products Administration for Phase I clinical trials of License Product 1 in China. License Product 2 is in the preclinical research stage. The signing of this License Agreement aligns with the company's overall development strategy, enriches the company's R&D pipeline, improves the company's market layout, provides treatment options for unmet clinical needs in the market, and will have a positive impact on the company's ongoing operations. This transaction will not have a significant impact on the company's recent production and operations, financial condition, and operating results. The signing of this agreement will not change the company's main business or scope of operations, will not affect the company's independence, and will not harm the interests of the company and shareholders.